Press Releases

Press Releases - Current

  December 11, 2015
CEL-SCI Reports Fiscal 2015 Financial Results and Clinical & Corporate Developments
  December 4, 2015
CEL-SCI's CEO Presentation Available On Company Website
  December 1, 2015
CEL-SCI Reports Monthly Patient Enrollment in November for Its Phase 3 Head and Neck Cancer Trial
  November 30, 2015
CEL-SCI Corporation To Present At The LD Micro Main Event
  November 17, 2015
CEL-SCI Is Granted a New European Patent on Its Phase 3 Investigational Cancer Immunotherapy Multikine
  November 4, 2015
CEL-SCI's Rheumatoid Arthritis Vaccine Selected for Commercialization & Program Niche Analysis Plan by U.S. National Institutes of Health
  November 2, 2015
CEL-SCI Reports Record Monthly Patient Enrollment in October for Its Phase 3 Head and Neck Cancer Trial
  October 28, 2015
CEL-SCI Announces Closing of Public Offering for Gross Proceeds of $11.5 Million
  October 23, 2015
CEL-SCI Prices Public Offering For Up To $12 Million
  October 22, 2015
CEL-SCI Announces Proposed Public Offering of Common Stock and Warrants
  October 19, 2015
CEL-SCI Corporation Releases Letter to Shareholders
  October 14, 2015
CEL-SCI to Receive Up to $5,000,000 in Litigation Funding to Support Its Arbitration Suit Against Former CRO
  October 5, 2015
Ergomed Increases Its Co-Development Contribution Up To $12,000,000 In CEL-SCI's Phase 3 Head and Neck Cancer Trial
  October 1, 2015
CEL-SCI Reports September Patient Enrollment for Its Phase 3 Head and Neck Cancer Trial
  September 1, 2015
CEL-SCI Reports August Patient Enrollment for Its Phase 3 Head and Neck Cancer Trial
  August 7, 2015
CEL-SCI Corporation Reports Third Quarter Fiscal Year 2015 Financial Results
  August 3, 2015
CEL-SCI Reports Record Monthly Patient Enrollment in July for Its Phase 3 Head and Neck Cancer Trial
  July 20, 2015
CEL-SCI Expands Its Phase I Study For Treatment of Anal Warts in HIV/HPV Co-Infected Patients with Addition of 2nd Site at University of California San Francisco
  July 1, 2015
CEL-SCI Reports June Patient Enrollment in Its Phase 3 Head and Neck Cancer Trial
  June 16, 2015
CEL-SCI to Present at the 2015 Bio International Convention
  June 8, 2015
CEL-SCI is Cleared to Start Patient Enrollment for Its Phase 3 Cancer Immunotherapy Trial in Thailand
  June 1, 2015
CEL-SCI Reports May Patient Enrollment in Its Phase 3 Head and Neck Cancer Trial
  May 29, 2015
CEL-SCI Announces Closing of Public Offering for Gross Proceeds of $16 Million
  May 27, 2015
CEL-SCI to Present at the 2015 Marcum MicroCap Conference
  May 22, 2015
CEL-SCI Prices Up To $16 Million Public Offering of Common Stock and Warrants
  May 21, 2015
CEL-SCI Announces Proposed Public Offering of Common Stock and Warrants
  May 13, 2015
CEL-SCI Receives Authorization to Conduct Its Phase 3 Multikine Trial in Italy
  May 11, 2015
CEL-SCI Receives Authorization to Conduct Its Phase 3 Multikine Trial in Spain
  May 8, 2015
CEL-SCI Corporation Reports Second Quarter Fiscal Year 2015 Financial Results
  May 6, 2015
CEL-SCI Announces Proposed Public Offering of Common Stock
  May 1, 2015
CEL-SCI Reports 4th Consecutive Month of Record Patient Enrollment in 2015 for Its Phase III Head and Neck Cancer Trial
  April 13, 2015
UK's Aintree University Hospital Joins CEL-SCI's Phase III Head and Neck Cancer Trial
  April 1, 2015
CEL-SCI Reports 3rd Consecutive Month of Record Patient Enrollment in 2015 for Its Phase III Head and Neck Cancer Trial
  March 3, 2015
CEL-SCI Reports 2nd Consecutive Month of Record Patient Enrollment in 2015 for Its Phase III Head and Neck Cancer Trial
  February 27, 2015
CEL-SCI Completes Key Milestone with Clearance to Conduct Phase III Trial in 21 Countries
  February 20, 2015
CEL-SCI to Participate in Ascendiant's Quarterly Management Discussion Series Today, Friday February 20 at 11 AM Eastern Time
  February 19, 2015
CEL-SCI's Phase III Head and Neck Cancer Trial Cleared to Begin Patient Enrollment in Malaysia, the 20th Country to Join the Trial
  February 18, 2015
CEL-SCI to Present At 3rd Annual Sachs Cancer Bio Partnering and Investment Forum
  February 11, 2015
The Philippines is the 19th Country to Clear CEL-SCI for Patient Enrollment in Its Phase III Head and Neck Cancer Trial
  February 6, 2015
CEL-SCI Corporation Reports First Quarter 2015 Financial Results
  February 5, 2015
CEL-SCI to Present At 17th Annual BIO CEO & Investor Conference
  February 2, 2015
CEL-SCI Reports Record Monthly Patient Enrollment in Its Phase III Head and Neck Cancer Trial
  January 26, 2015
CEL-SCI Receives Regulatory Clearance to Expand Its Phase III Head and Neck Cancer Trial into Romania
  January 9, 2015
CEL-SCI to Present at Biotech Showcase 2015
  January 6, 2015
Date Set For Arbitration Trial between CEL-SCI And Clinical Research Organization Inventiv
  January 5, 2015
CEL-SCI's 2014 Patient Enrollment Increases Eight-Fold Over 2013 in Its Phase III Head and Neck Cancer Trial

Press Releases - 2014

Press Releases - 2013

Press Releases - 2012

Press Releases - 2011